FogPharma bags $145M, adds Alexis Borisy to the board 

Fog­Phar­ma, a biotech from Har­vard re­searcher Greg Ver­dine that is led by for­mer John­son & John­son R&D leader Math­ai Mam­men, said it has raised $145 mil­lion in a Se­ries E fi­nanc­ing.

The nine-fig­ure round, biotech’s 13th of 2024, was led by Nex­tech In­vest and in­clud­ed par­tic­i­pa­tion from Alex Gorsky, Mam­men’s for­mer boss at J&J.

The Boston-area biotech is one of a few drug de­vel­op­ers to raise that many pri­vate rounds be­fore a move to the pub­lic mar­kets. The biotech last dis­closed a $178 mil­lion Se­ries D in No­vem­ber 2022.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.